ABVX:EPA
Abivax SA
78,70 €
arrow_downward
-0,51%(-0,40) 1D
16 նոյ, 15:47:59 GMT+1 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ABVX...
Open
79,00 €
High
80,05 €
Low
78,15 €
Mkt. cap
6,89 մլրդ
Avg. vol.
109,70 հզր
Volume
21,01 հզր
52-wk high
139,00 €
52-wk low
60,45 €
EPS
-5,20 €
Shares outstanding
87,55 մլն
No. of employees
98
Open
79,00 €
High
80,05 €
Low
78,15 €
Mkt. cap
6,89 մլրդ
Avg. vol.
109,70 հզր
Volume
21,01 հզր
52-wk high
139,00 €
52-wk low
60,45 €
EPS
-5,20 €
Shares outstanding
87,55 մլն
No. of employees
98
News stories
From web sources and news partners
upi
·
22 րոպե առաջ
KB Kookmin Bank debuts S&P 500-linked dollar deposit product
ChartMill
·
1 ժամ առաջ
S&P 500 Premarket Losers on Nov. 16, 2026: COIN, LITE, COHR
Investing.com
·
2 ժամ առաջ
Dow Jones, Nasdaq, S&P 500 weekly preview: Nvidia earnings, Anthropic IPO on deck
FXEmpire
·
1 ժամ առաջ
Why The S&P 500 Could Fall 63% – And Still Only Be Fairly Valued
Profile
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
Abivax has a program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated.
The company’s headquarters are based in Paris, France with a US office in Waltham, Massachusetts. Abivax’s Research and development work is conducted at its research center based in Montpellier, France. Wikipedia
About Abivax SA
CEOMarc de Garidel | Hartmut J. Ehrlich
Employees98
Founded04 դեկ, 2013 թ.
Headquarters-
SectorHealth Care
Industry-
Websiteabivax.com